Thomas Jefferson Opens New Familial Colorectal Cancer Registry

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 2
Volume 7
Issue 2

PHILADELPHIA-Thomas Jefferson University’s new Familial Colorectal Cancer Registry is collecting information and blood and tissue samples from families with a higher-than-normal risk of colon cancer, to aid researchers looking for genetic markers of the disease and to provide genetic counseling and genetic testing, if appropriate, to participants.

PHILADELPHIA—Thomas Jefferson University’s new Familial Colorectal Cancer Registry is collecting information and blood and tissue samples from families with a higher-than-normal risk of colon cancer, to aid researchers looking for genetic markers of the disease and to provide genetic counseling and genetic testing, if appropriate, to participants.

To date, 35 members of 24 families have been enrolled. Operations director Deborah Rose said she expects to have hundreds of new registry members in the next year.

Typically, a patient is referred to the registry by a physician, family member, or self-referral. To participate, patients may have either a personal or family history of a particular type of inherited colorectal cancer, such as familial adenomatous polyposis or hereditary nonpolyposis colorectal cancer.

Others who are eligible include those who have had colorectal cancer diagnosed before age 30 and patients with a first-degree relative diagnosed with colorectal cancer before age 50.

For more information about the registry and clinical genetic testing, patients and physicians may call 1-800-JEFF-NOW (1-800-533-3669).

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Related Content